1. Wei L, Kamae I, Lee MH, Li H. Hepatitis C viral infection disease burden in Asia. Value Outcomes Spotlight 2015;1:16–18. 3. Kondili LA, Craxì A, Aghemo A. Absolute targets for HCV elimination and national health policy paradigms: foreseeing future requirements. Liver Int 2021;41:649–655.

4. Kim HL, Kim KA, Choi GH, et al. A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: a societal perspective. Clin Mol Hepatol 2022;28:91–104.

5. Chhatwal J, Chen Q, Ayer T, et al. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther 2018;47:1023–1031.

6. Shon HS, Choi HY, Kim JR, et al. Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005–2012. Clin Mol Hepatol 2015;21:249–256.

7. Sohn HS, Kim JR, Ryu SY, et al. Risk factors for hepatitis C virus (HCV) infection in areas with a high prevalence of HCV in the Republic of Korea in 2013. Gut Liver 2016;10:126–132.

8. Chung JW, Choi HY, Ki M, Jang ES, Jeong SH. Comorbidities and prescribed medications in Korean patients with chronic hepatitis C: a nationwide, population-based study. Gut Liver 2021;15:295–306.

9. Devarbhavi H, Aithal G, Treeprasertsuk S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int 2021;15:258–282.

10. Mangia A, Scaglione F, Toniutto P, et al. Drug-drug interactions in Italian patients with chronic hepatitis C treated with pangenotypic direct acting agents: insights from a real-world study. Int J Environ Res Public Health 2021;18:7144.

11. American Association for the Study of Liver Diseases (AASLD). Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy [Internet] Virginia (GA): The Infectious Diseases Society of America, 2022. [cited 2021 Nov 30]. Available from: https://www.hcvguidelines.org/evaluate/monitoring . 12. World Health Organization (WHO). Interim Guidance for Country Validation of Viral Hepatitis Elimination. Geneva: WHO, 2021. 13. Kim L, Kim JA, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health 2014;36:e2014008.

14. Kim J. The cross-validation of Samsung Medical Center’s clinical terminology to KCD-7 and SNOMED to ICD-10 mappings. In : SNOMED CT Expo; 2020 Oct 8–9. 15. Steiner S, Raguž-Lučić N, Erceg D. Direct-acting antivirals (DAAs): drug-drug interactions (DDIs) in the treatment of hepatitis C virus (HCV). In: Smolic M, Vcev A, Wu G, eds. Update on Hepatitis C. London: IntechOpen, 2017.

16. Jang ES, Ki M, Choi HY, Kim KA, Jeong SH, Korean Hepatitis Epidemiology Study Group. The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015. Hepatol Int 2019;13:599–608.

17. Mohammed Abdul MK, Snyder HS, Chunduru M, Lee SMK, Satapathy SK. Hepatitis C virus in the elderly in the direct-acting antiviral era: from diagnosis to cure. Curr Treat Options Infect Dis 2020;12:296–309.

18. Salive ME. Multimorbidity in older adults. Epidemiol Rev 2013;35:75–83.

19. Chang KC, Tung SY, Wei KL, et al. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. Sci Rep 2021;11:13543.